Neurocrine Biosciences Inc
NASDAQ:NBIX

Watchlist Manager
Neurocrine Biosciences Inc Logo
Neurocrine Biosciences Inc
NASDAQ:NBIX
Watchlist
Price: 147.6 USD 0.51%
Market Cap: 14.6B USD

Neurocrine Biosciences Inc
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Neurocrine Biosciences Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Neurocrine Biosciences Inc
NASDAQ:NBIX
Pre-Tax Income
$628.6m
CAGR 3-Years
97%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$1.7B
CAGR 3-Years
-52%
CAGR 5-Years
-27%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$9.9B
CAGR 3-Years
30%
CAGR 5-Years
41%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$8.2B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$4.4B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5.1B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
16%
No Stocks Found

Neurocrine Biosciences Inc
Glance View

Neurocrine Biosciences Inc. is a biopharmaceutical company that has carved out a notable niche in the neurosciences landscape. Founded in 1992, this San Diego-based firm has dedicated itself to developing treatments for neurological and endocrine-related disorders. With a strong focus on conditions such as Parkinson's disease, tardive dyskinesia, and epilepsy, Neurocrine leverages its expertise in neuroscience to bring innovative therapies to those who need them most. The company’s flagship product, Ingrezza, primarily used to treat tardive dyskinesia, reflects their commitment to addressing complex, unmet medical needs. Successfully obtaining FDA approval not only boosted patient outcomes but also established Neurocrine as a leader in a specialized segment of the pharmaceutical industry. Neurocrine’s financial model thrives on the commercialization of its proprietary medications. By partnering strategically with other pharmaceutical giants, such as AbbVie, they can broaden their market reach and accelerate development of new treatments. The company generates revenue predominantly through product sales, royalties, and milestone payments associated with its collaborations. Their pipeline remains robust, focusing on both expanding indications for existing drugs and pioneering new treatments. Each new approval or advancement in clinical trials further solidifies their market position and offers potential for increased financial returns. Thus, Neurocrine Biosciences operates at the intersection of science and business, continuously pushing the boundaries of neurological treatment while maintaining a steady growth trajectory.

NBIX Intrinsic Value
147.38 USD
Fairly Valued
Intrinsic Value
Price

See Also

What is Neurocrine Biosciences Inc's Pre-Tax Income?
Pre-Tax Income
628.6m USD

Based on the financial report for Sep 30, 2025, Neurocrine Biosciences Inc's Pre-Tax Income amounts to 628.6m USD.

What is Neurocrine Biosciences Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
43%

Over the last year, the Pre-Tax Income growth was 21%. The average annual Pre-Tax Income growth rates for Neurocrine Biosciences Inc have been 97% over the past three years , 43% over the past five years .

Back to Top